This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 Big Biotechs Hold Growth Potential in Second Half of 2019
by Ekta Bagri
We highlight a few leading players from the biotech sector, having surpassed the same so far in 2019 and are likely to put up a good show during the second half of 2019 as well.
The Zacks Analyst Blog Highlights: Deere, Las Vegas Sands, Vertex, Tesla and Keurig Dr Pepper
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Deere, Las Vegas Sands, Vertex, Tesla and Keurig Dr Pepper
Top Stock Reports for Deere, Las Vegas Sands & Vertex
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Deere (DE), Las Vegas Sands (LVS) and Vertex (VRTX).
Glaxo Inks Genome Research Deal With University of California
by Zacks Equity Research
Glaxo (GSK) signs a five-year collaboration contract with the University of California to build a new laboratory for developing new medicines with the aid of CRISPR technologies.
Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash
by Zacks Equity Research
Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
CELG or VRTX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CELG vs. VRTX: Which Stock Is the Better Value Option?
CRISPR Therapeutics Up on Collaboration Expansion by Vertex
by Zacks Equity Research
CRISPR Therapeutics (CRSP) is set to receive $175 million in upfront payment from Vertex following the expansion of the collaboration agreement for gene editing program to include new disease areas.
Vertex Expands Collaboration With CRISPR, Acquires Exonics
by Zacks Equity Research
Vertex (VRTX) is expanding its gene editing pipeline into new disease areas by expanding collaboration with CRISPR Therapeutics and acquiring Exonics.
The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne
5 Biotech Stocks to Buy Right Now
by Zachary Stutler
here are a few stocks that have outperformed their peers and are expected to have continued growth throughout the next couple of years. All the stocks in this list are a Zacks Rank #2 (Buy) or better.
Vertex Selects Triple Combo Regimen for Regulatory Submission
by Zacks Equity Research
Vertex (VRTX) choses VX-445 triple combination regimen for global regulatory submissions to seek approval for the regimen as a treatment for cystic fibrosis based on 24-week phase III study data.
Why Is Vertex (VRTX) Down 3.5% Since Last Earnings Report?
by Zacks Equity Research
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CELG or VRTX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CELG vs. VRTX: Which Stock Is the Better Value Option?
Biotech Stock Roundup: Label Expansion for CELG's Drugs, Setback for IMGN
by Zacks Equity Research
Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
CELG vs. VRTX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CELG vs. VRTX: Which Stock Is the Better Value Option?
Proteostasis (PTI) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
During Proteostasis' (PTI) Q1 earnings call, investor focus will be on its update pertaining to the progress of studies, evaluating its triple combination regimes for cystic fibrosis.
The Zacks Analyst Blog Highlights: Biogen, Celgene, Incyte, Alexion and Vertex
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Biogen, Celgene, Incyte, Alexion and Vertex
Biotech Stock Roundup: BIIB, VRTX, ALXN Q1 Earnings Top & Other Pipeline Updates
by Zacks Equity Research
Key highlights of the past week are earnings releases by most leading biotech entities.
Vertex (VRTX) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Vertex (VRTX) beats on both earnings and sales in Q1 with demand for its newest CF drug, Symdeko, rising high.
Will Vertex (VRTX) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
What's in Store for Vertex (VRTX) This Earnings Season?
by Zacks Equity Research
On Vertex's (VRTX) first-quarter earnings call, investor focus will be on its latest CF drug Symdeko's sales figure as well as the update on its CF triple-pill regimes.
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: GILD Collaborates on NASH, FCSC Surges on Deal
by Zacks Equity Research
Key highlights of the past week are collaborations and pipeline updates.
Vertex, CRISPR's Gene Editing Drug Gets FDA's Fast Track Tag
by Zacks Equity Research
FDA grants a Fast Track designation to Vertex (VRTX) and CRISPR Therapeutics' gene editing candidate, CTX001, for a second indication - transfusion-dependent beta thalassemia.
4 Small Biotech Stocks Likely to Witness More Upside in 2019
by Zacks Equity Research
The biotech space is witnessing a rally so far in 2019. Here we discuss four stocks that are likely to witness a continuation of the uptrend going ahead.